Characterization of the Long-term Safety, Efficacy, and Pharmacodynamics Revestive® in the Management of Short Bowel Syndrome Pediatric Patients (REVE)

Assistance Publique - Hôpitaux de Paris

Status and phase

Completed

Phase 4

Conditions

Short Bowel Syndrome

Treatments

Drug: Teduglutide

Study type

Interventional

Funder types

Other

Identifiers

NCT03562130

P171002J

2017-001405-32 (EudraCT Number)

Details and patient eligibility

About

The purpose of this study is to evaluate if the treatment could maximize intestinal absorption, minimize the inconvenience of diarrhea, and avoid, reduce or eliminate the need for parenteral support (PS) to achieve normal growth, to avoid parenteral nutrition complications and to achieve the best possible quality of life for the patient

Full description

The short bowel syndrome (SBS) may be defined as a severe malabsorption caused by reduction of intestinal absorptive surface following massive resection of the small intestine. Teduglutide (Revestive®) is an analog of glucagon-like peptide 2 (GLP-2), a naturally occurring hormone that regulates the functional and structural integrity of the cells lining the gastrointestinal tract. The aim of the treatment is to maximize intestinal absorption, minimize the inconvenience of diarrhea, and avoid, reduce or eliminate the need for parenteral support (PS) to achieve the best possible quality of life for the patient. The rationale for the use of Revestive® is based on data obtained, especially in the trial in SBS patients.

Treatment with 0.05 mg/kg/day was safe and well tolerated (no recorded side effects).

Patients remained stable despite substantial reduction in parenteral nutrition (PN) supply as evidenced by stable body weight and height, serum electrolytes, pancreatic enzymes and renal function tests.

Treatment was associated with:

Reduced PN volume and calories delivered by 25 and 45% respectively with 20% of patients weaned off PN during the study period
Increased Enteral Nutrition (EN) supply in volume and calories by 40 and 62% respectively
Increased in plasma citrulline during the treatment period, but decreased after Teduglutide discontinuation The recommended dose of Revestive® in children and adolescents (aged 1 to 17 years) is the same as for adults (0.05 mg/kg body weight once daily).

Enrollment

25 patients

Sex

All

Ages

2 to 18 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Being aged from 2 to 18 years old included ;
Presenting less than 80 cm of residual small intestine with or without the terminal ileum, ileocecal valve and right colon or having less than 120 cm in case of Short Bowel Syndrome (SBS) caused by Hirschsprung disease;
Being stable on PN support (inability to significantly reduce PN intake for the last six months before inclusion) ;
Being dependent on PN for at least 2 years and enterally fed (oral or tube feeding) ;
Having a normal colonoscopy in the 12 months before screening for children with maintained colon (=SBS type 2 or 3) older than 12 years ;
Having signed the Informed consent form (or parents or legal representative for minor patients).

Exclusion criteria

Having a major gastrointestinal surgical intervention like serial transverse enteroplasty or any other bowel lengthening procedure performed within 6 months of screening ;
Having a clinically significant untreated intestinal obstruction or active stenosis ;
Having an unstable absorption due to cystic fibrosis or known DNA abnormalities ;
Presenting a radiographic or manometric evidence of pseudo-obstruction or severe known dysmotility syndrome, including persistent, severe gastroschisis-related motility disorders ;
Having an unstable cardiac disease, congenital heart disease or cyanotic disease, with the exception of patients who had undergone ventricular or atrial septal defect repair ;
Having a history of cancer or clinically significant lymphoproliferative disease; excepted resected cutaneous basal or squamous cell carcinoma, or in situ non-aggressive and surgically resected cancer ;
Having participated in a clinical study using an experimental drug within 1 month or an experimental antibody treatment within 3 months prior to screening, or concurrent participation in any clinical study using an experimental drug that would affect the safety of teduglutide ;
Having already used native GLP-2 and glucagon-like peptide-1 analog or human growth hormone within 3 months prior to screening ;
Having already used oral or IV glutamine, octreotide, or dipeptidyl peptidase IV (DPP-IV) inhibitors within 3 months prior to screening ;
Having an active Crohn's disease which has been treated with biological therapy within the 6 months prior to screening ;
Having an intestinal polyposis;
Being, for female patient, both lactating and breast-feeding or having a positive pregnancy test during the screening period;
Refusing the follow the protocol requirements in terms of birth control ;
Being unable to follow the study procedures for any reason: psychological, geographical…
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 of Summary of Product Characteristics (SPC), or trace residues of tetracycline.
Active or suspected malignancy.
Patients with a history of malignancies in the gastrointestinal tract including the hepatobiliary system within the last five years.